Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences
- 1 January 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 156 (1) , 13-19
- https://doi.org/10.1530/eje.1.02310
Abstract
Acute hypothyroidism induced by thyroid hormone withdrawal in patients with differentiated thyroid cancer during monitoring for remnant or metastatic disease, seriously affects multiple organs and systems, and especially in severe cases can impair quality of life. Indeed, it may induce untoward cardiovascular effects and can be hazardous in patients with underlying cardiovascular disease, particularly in the elderly. Moreover, acute hypothyroidism deranges the lipid profile and exacerbates neuropsychiatric illness. The introduction of recombinant human TSH (rhTSH) as a diagnostic and therapeutic tool in the care of patients with thyroid cancer has widened the scope of disease management. The use of rhTSH prevents derangement of various systems at approximately equivalent societal costs to that of withdrawal and promotes compliance while preserving the patient’s normal daily functioning and productivity. Its reliability allied with its safety render this compound a valid alternative in the monitoring of patients with differentiated thyroid carcinoma as well as providing an alternative therapeutic procedure whenever LT4-withdrawal may be hazardous or in cases of patient non-compliance.Keywords
This publication has 53 references indexed in Scilit:
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- Managing Small Thyroid CancersJAMA, 2006
- Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus reportActa Endocrinologica, 2005
- Recombinant Human Thyrotropin is Helpful in the Follow-Up and 131I Therapy of Patients with Thyroid Cancer: A Report of the Results and Benefits Using Recombinant Human Thyrotropin in Clinical RoutineThyroid®, 2005
- Controversies in the follow-up and management of well-differentiated thyroid cancer.Endocrine-Related Cancer, 2004
- Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspectiveActa Endocrinologica, 2004
- A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2003
- A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or CancerJournal of Clinical Endocrinology & Metabolism, 1999
- Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid CarcinomaNew England Journal of Medicine, 1997
- Treatment Guidelines for Patients With Thyroid Nodules and Well-Differentiated Thyroid CancerArchives of internal medicine (1960), 1996